|
所属 |
大学院医学系研究科（医学専攻等） 医学専攻 腫瘍制御医学系 腎泌尿器科学講座 |
|
研究室住所 |
秋田市本道1-1-1、秋田大学大学院医学系研究科 腎泌尿器科学教室 |
|
研究室電話 |
018-884-6156 |
|
研究室FAX |
018-836-2619 |
|
ホームページ |
|
|
プロフィール |
1961年京都市生まれ、 |
羽渕 友則 (ハブチ トモノリ)
HABUCHI Tomonori
|
|
|
職務経歴（学内） 【 表示 ／ 非表示 】
-
2022年04月-継続中
秋田大学 大学院医学系研究科 研究科長
-
2009年04月-継続中
秋田大学 大学院医学系研究科（医学専攻等） 医学専攻 腫瘍制御医学系 教授
研究等業績 【 表示 ／ 非表示 】
-
Ozaki K.
World Journal of Urology ( World Journal of Urology ) 41 ( 1 ) 67 - 75 2023年01月
研究論文（学術雑誌）
PURPOSE: We compared the real-world efficacy and medical costs for treatment with upfront docetaxel (DOC) and abiraterone acetate (ABI) up to progression-free survival 2 (PFS2) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). METHODS: This multicenter retrospective study included 340 patients with mHSPC treated with either upfront DOC or upfront ABI between October 2015 and December 2021. We compared PFS2 and medical costs between the two treatment groups. PFS2 was defined as the time from first-line therapy to progression on second-line therapy. Medical costs were estimated using the National Health Insurance drug prices in 2022 in Japan. RESULTS: The upfront DOC and ABI groups included 107 and 233 patients, respectively. The incidence of metastatic castration-resistant PC progression was significantly higher in the upfront DOC group compared with the incidence in the upfront ABI group. However, no significant differences in PFS2 were observed between the two treatment groups. Monthly medical costs per patient were significantly higher in the upfront ABI group ($3453) compared with the costs in the upfront DOC group ($1239, P < 0.001). The cost differences were significantly influenced by differences in the length of androgen deprivation therapy monotherapy (DOC group, 13.4 months vs. ABI group, 0.0 months). CONCLUSIONS: We observed a significant cost benefit in the upfront DOC group in Japanese real-world practice, while the PFS2 rates were similar between the groups. Upfront DOC was a more cost-effective option for men with mHSPC who were eligible for toxic chemotherapy.
-
Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma.
Yoshiharu Okuyama, Shingo Hatakeyama, Kazuyuki Numakura, Takuma Narita, Toshikazu Tanaka, Yuki Miura, Daichi Sasaki, Daisuke Noro, Noriko Tokui, Teppei Okamoto, Hayato Yamamoto, Shintaro Narita, Takahiro Yoneyama, Yasuhiro Hashimoto, Tomonori Habuchi, Chikara Ohyama
BJUI compass 3 ( 2 ) 154 - 161 2022年03月
研究論文（学術雑誌）
OBJECTIVE: To evaluate the effects of the concomitant use of proton pump inhibitors (PPIs) and/or antibiotics (Abs) on oncological outcomes in patients with advanced urothelial carcinoma. PATIENTS AND METHODS: We retrospectively evaluated 155 patients with advanced urothelial carcinoma who were treated with immune checkpoint inhibitors (ICIs) between August 2015 and April 2021. The concomitant use of PPI or Abs was defined as any PPI or Abs administered within 30 days before ICI initiation and during ICI therapy. The primary outcomes were the effect of PPI and/or Abs use on the objective response rate (ORR) and immune-related adverse events (irAEs). The secondary outcomes were the effects of PPI and/or Abs use on progression-free survival (PFS) and overall survival (OS) after ICI therapy analyzed using the inverse probability of treatment weighting-adjusted Cox regression analysis. RESULTS: Of the 155 patients enrolled in the study, 99 (64%) were PPI users and 56 (36%) Abs users. PPI users were associated with a significantly poorer ORR than non-PPI users (41% vs. 20%, respectively), whereas Abs use was not significantly associated with changes in ORR. The rate of irAEs was not significantly associated with the use of PPIs or Abs. Multivariate inverse probability of treatment weighting-adjusted Cox regression analysis revealed significantly poorer PFS and OS in PPI users than in non-PPI users, whereas Abs use was not associated with poorer outcomes. CONCLUSION: The concomitant use of PPI may adversely affect oncological outcomes in patients with locally advanced or metastatic urothelial carcinoma treated with ICI therapy.
-
Hands on training in the laparoscopic living-donor nephrectomy
Mitsuru Saito, Shintaro Narita, Tomonori Habuchi
Japanese Journal of Clinical Urology 75 ( 10 ) 730 - 735 2021年
研究論文（学術雑誌）
-
Robotic-assisted laparoscopic partial nephrectomy for renal cell carcinoma in horseshoe kidney: a hybrid technique with conventional laparoscopic surgery.
Kazuyuki Numakura, Yumina Muto, Ryohei Yamamoto, Atsushi Koizumi, Taketoshi Nara, Sohei Kanda, Mitsuru Saito, Shintaro Narita, Takamitsu Inoue, Tomonori Habuchi
International cancer conference journal 9 ( 4 ) 199 - 202 2020年10月
研究論文（学術雑誌）
Robotic-assisted laparoscopic partial nephrectomies (RAPN) have come up to standard treatment for small renal tumors, with a growing indication to accomplish this procedure. Although a horseshoe kidney is one of the most common congenital renal fusion anomalies, surgical planning for tumors is considered difficult because of its poor mobility and abnormal vascular supply. We showed our experience of RAPN in combination with conventional laparoscopic kidney mobilization and dissection for a patient with renal cell carcinoma in a horseshoe kidney. The patient was an otherwise healthy 66-year-old man with 26 mm right renal mass on the lower pole of the horseshoe kidney. Robotic assistance allows for proper tissue dissection, easy to aware unconfirmed vasculatures, and meticulous fine suturing and would overcome the potential challenges involved in the minimally invasive management of such complex anomalies as shown in the patient.
-
Follow-up of patients with bladder cancer
Shintaro Narita, Tomonori Habuchi, Yoshiyuki Matsui, Toyonori Tsuzuki
Japanese Journal of Clinical Urology 74 ( 5 ) 320 - 325 2020年
研究論文（学術雑誌）
-
Yanagisawa T.
Prostate ( Prostate ) 83 ( 6 ) 563 - 571 2023年
-
Shiota M.
Cancer Science ( Cancer Science ) 2023年
Genetic variations represented by single-nucleotide polymorphisms (SNPs) could be helpful for choosing an effective treatment for patients with prostate cancer. This study investigated the prognostic and predictive values of SNPs associated with the prognoses of pharmacotherapy for prostate cancer through their pharmacological mechanisms. Patients treated with docetaxel or androgen receptor pathway inhibitors (ARPIs), such as abiraterone and enzalutamide, for castration-resistant prostate cancer were included. The SNPs of interest were genotyped for target regions. The prognostic and predictive values of the SNPs for time to progression (TTP) were examined using the Cox hazard proportional model and interaction test, respectively. Rs1045642 in ABCB1, rs1047303 in HSD3B1, rs1856888 in HSD3B1, rs523349 in SRD5A2, and rs34550074 in SLCO2A1 were differentially associated with TTP between docetaxel chemotherapy and ARPI treatment. In addition to rs4775936 in CYP19A1, rs1128503 in ABCB1 and rs1077858 in SLCO2B1 might be differentially associated with TTP between abiraterone and enzalutamide treatments. Genetic predictive models using these SNPs showed a differential prognosis for treatments. This study identified SNPs that could predict progression as well as genetic models that could predict progression when patients were treated with docetaxel versus ARPI and abiraterone versus enzalutamide. The use of genetic predictive models is expected to be beneficial in selecting the appropriate treatment for the individual patient.
-
Habuchi T.
European Urology ( European Urology ) 2023年
-
Numakura K.
World Journal of Surgical Oncology ( World Journal of Surgical Oncology ) 20 ( 1 ) 202 - 202 2022年12月
INTRODUCTION: Warm ischemia time (WIT) is a primary concern for robot-assisted laparoscopic partial nephrectomy (RALPN) patients because longer WIT is significantly associated with postoperative deteriorating kidney function. Tumor complexity, determined by the RENAL nephrometry score (RENAL score), can help predict surgical outcomes, but it is unclear what RENAL score and clinical factors affect WIT. This study explored the clinical factors predicting long WIT in experienced surgeon to RALPN. MATERIALS AND METHODS: In our institute, 174 RALPNs were performed between November 2013 and February 2021, of which 114 were performed by a single surgeon and included in this study. Clinical staging and the total RENAL score were determined based on preoperative CT scans. The cases were divided into three groups based on experience: period 1: 1-38, period 2: 39-76, and period 3: 77-114. The clinical factors associated with longer WIT were analyzed per period. RESULTS: The overall median tumor diameter was 32 mm, and one patient had a positive surgical margin, but there were no cancer-related deaths. In total, there were 18 complications (15.8%). Periods 2 and 3 had larger tumor diameters (p < 0.01) and worse preoperative kidney function (p = 0.029) than period 1. A RENAL L-component score of 3 was associated with longer WIT in period 3 (odds ratio: 3.900; 95% confidence interval: 1.004-15.276; p = 0.044), but the tumor diameter and the total RENAL score were not. CONCLUSIONS: A large tumor in the central lesion indicated by the RENAL L-component score was associated with increased WIT in RALPN.
-
Takayama K.
IJU Case Reports ( IJU Case Reports ) 5 ( 6 ) 517 - 520 2022年11月
Introduction: Complete remission of cerebral metastasis is a rare consequence of tyrosine kinase inhibitor monotherapy in patients with metastatic renal cell carcinoma. Case presentation: A 68-year-old woman, who presented with dyspnea, was diagnosed with left renal cell carcinoma with multiple brain and pleural metastases. Although nivolumab and ipilimumab combination treatment was initiated, it was discontinued because of an immune-related adverse event. Two months after treatment cessation, brain metastases progressed regardless of shrinkage of primary renal tumor and pleural metastases. Therefore, axitinib was started as a second-line treatment, which resulted in the complete disappearance of the brain metastases along with the stable disease of the other tumor lesions. Conclusion: This is the first report of complete remission of brain metastases in renal cell carcinoma treated by axitinib.
◆原著論文【 表示 ／ 非表示 】
◆その他【 表示 ／ 非表示 】
Book（書籍） 【 表示 ／ 非表示 】
-
A nation-wide laparoscopic skills qualification: A thirteen-year experience in Japan
Matsuda T. ( 担当： その他 )
Endourology Progress: Technique, Technology and training 2019年01月 ISBN: 9789811334641
For laparoscopic and robotic surgeries, the surgeons’ competency is important to keep high quality of surgical treatment. Japanese Society of Endourology (JSE) and the Japanese Urological Association established a urological laparoscopic skills evaluation system called the Endoscopic Surgical Skill Qualification (ESSQ) System in Urological Laparoscopy in 2004. By 2016, a total of 1463 urologists had qualified from a total of 2561 applicants after skills assessment on non-edited videos by two referees, resulting in a pass rate of 57.1%. Details of the system and the skill assessment results are shown. Prospectively collected surgical outcomes of 2590 laparoscopic urologic operations performed by 130 qualified doctors 5 years post-qualification were excellent, demonstrating the good predictive validity of the ESSQ System. The reliability of video assessments by referees was analyzed statistically on 1220 videos which had fixed points by two referees. The results showed moderate reliability for the video assessments by the referees, but the final qualification rates showed no significant differences among the referees, which indicated that the video assessments by the referees were fair for all applicants. In the 13 years since the launch of the ESSQ System, it has become the goal of young urologists in Japan who learn laparoscopic surgery. According to a nation-wide survey by JSE, open conversion rates and major complication rates have dramatically decreased during these 26 years since 1990.
-
Skeletal complications in patients with CRPC
Inoue T. ( 担当： その他 )
Hormone Therapy and Castration Resistance of Prostate Cancer 2018年05月 ISBN: 9789811070129
Skeletal complications in patients with prostate cancer can result in significant morbidity. There is a relatively high prevalence of bone metastasis and reduction of bone mineral density due to androgen deprivation therapy, and together, these can result in the development of multiple skeletal complications in patients with prostate cancer. The relatively long survival (median, 3-4 years) after bone metastases with multiple skeletal complications makes a significant negative impact on patients' functional status, quality of life, and social resource utilization. To evaluate skeletal complications, the term "skeletal-related events (SREs)" has frequently been used in most randomized trials conducted previously. SREs usually include pathological bone fracture, spinal cord compression, surgery to bone, and radiotherapy to the bone. Recently, symptomatic skeletal events (SSEs), including only symptomatic events, is the recommended term for use in clinical trials. Local therapies for skeletal complications, such as radiation and surgery, are usually performed to reduce local symptoms, such as bone pain or neurological deficits, leading to improvement of the health-related quality of life. Systemic therapies, such as radiopharmaceuticals, bisphosphonates, and monoclonal antibodies against the receptor activator of the nuclear factor-kappa B ligand, are administered to reduce presymptomatic and symptomatic skeletal complications.
-
Intermittent chemotherapy with docetaxel for metastatic castration-resistant prostate cancer
Narita S. ( 担当： その他 )
Hormone Therapy and Castration Resistance of Prostate Cancer 2018年05月 ISBN: 9789811070129
The optimal schedule of docetaxel chemotherapy for castration-resistant prostate cancer is unknown, although continuous administration is accepted as the standard. However, several disadvantages, including side effects, costs, and development of resistant clones, need to be considered during continuous administration of docetaxel. Intermittent docetaxel therapy represents an appealing option to address these issues. Previous studies have reported that intermittent docetaxel therapy is associated with favorable outcomes, with successful chemotherapy holidays and maintained Quality of Life (QOL). However, limitations of these studies include a wide variation in study design and schedule and a lack of randomized trials comprising a large number of patients allowing comparison of outcomes with continuous administration. This chapter summarizes current data on intermittent docetaxel therapy in androgen-independent and castration-resistant prostate cancer from previous literature and examines future directions regarding the use of this strategy as a therapeutic option for advanced prostate cancer.
-
ベッドサイド泌尿器科学
吉田, 修, 小川, 修, 岡田, 裕作, 荒井, 陽一, 寺地, 敏郎, 松田, 公志, 筧, 善行, 羽渕, 友則 ( 担当： その他 )
南江堂 2013年05月 ISBN: 9784524250370
その他
科研費（文科省・学振）獲得実績 【 表示 ／ 非表示 】
-
食と肥満による腸内細菌叢異常と泌尿器癌進展と治療抵抗性の分子機構解明と制御
基盤研究(B)
研究期間: 2021年04月 - 2025年03月 代表者: 羽渕 友則, 堂前 直, 嘉島 相輝, 南條 博, 土谷 順彦, 大山 力, 沼倉 一幸
-
Adiposity亢進に伴う腫瘍免疫微少環境変化と泌尿器癌進展の分子機構解明
基盤研究(A)
研究期間: 2016年04月 - 2021年03月 代表者: 羽渕 友則, 南條 博, 土谷 順彦, 大山 力, 沼倉 一幸, 前野 淳
-
前立腺癌の過剰診断と過剰治療を回避する糖鎖バイオマーカーの実用化
基盤研究(A)
研究期間: 2015年04月 - 2020年03月 代表者: 大山 力, 羽渕 友則, 畠山 真吾, 坪井 滋, 盛 和行, 米山 徹, 橋本 安弘, 米山 高弘, 古家 琢也, 飛澤 悠葵
-
免疫学的ハイリスク腎移植における抗CD20抗体投与後のB細胞免疫応答機構の解明
基盤研究(C)
研究期間: 2015年04月 - 2019年03月 代表者: 齋藤 満, 羽渕 友則, 佐藤 滋, 南条 博, 井上 高光, 山本 竜平, 水戸部 陽子
-
日本人前立腺癌患者に対するホルモン療法の有害事象の検証と対策
基盤研究(C)
研究期間: 2015年04月 - 2018年03月 代表者: 三塚 浩二, 安達 尚宣, 荒井 陽一, 川崎 芳英, 喜屋武 淳, 佐藤 友紀, 折笠 一彦, 宮里 実, 青木 大志, 成田 伸太郎, 古家 琢也, 栃木 達夫, 羽渕 友則, 大山 力